Respondents to a recent GEN poll appear divided on how useful FDA legislation designed to speed up drug approvals, and now sailing through Congress, will be on improving the investment climate. More than one-third of respondents (37.5%) believe the measure will be “somewhat” useful, but another one-third-plus (35%) answered “not very useful.” Another 27.5% said the legislation will be “very” useful; no respondents were undecided.

Key committees of the Senate and House of Representatives have marked up bills combining a fifth reauthorization of the Prescription Drug User Fee Act (PDUFA V) with provisions based on predecessor bills that include the Faster Access to Specialized Treatments (FAST) Act introduced in the House of Representatives, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act introduced in the Senate, and another Senate bill, the Advancing Breakthrough Therapies for Patients Act of 2012.

Previous articleSolvo, XenoBiotic to Provide In Vitro Transporter Services in the U.S.
Next articleRuga Licenses Selexagen’s RAF Kinase Program for Targeted Cancer Therapy